Imad Khdair, MD
Internal Medicine · Sylacauga, ALNPI 1093725624
Payments from drug & device makers
Across 154 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$354
- AbbVie$317
- Pfizer$285
- Bayer$237
- Novartis$156
- AstraZeneca$147
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,42997%
- Education$733%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $354 |
| AbbVie(2 entities) | 24 | $317 |
| Pfizer | 19 | $285 |
| Bayer | 13 | $237 |
| Novartis | 9 | $156 |
| AstraZeneca | 7 | $147 |
| Dexcom, Inc. | 7 | $109 |
| GSK | 6 | $96 |
| Amgen | 6 | $93 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Corcept Therapeutics | 3 | $71 |
| Ardelyx, Inc. | 3 | $67 |
| Johnson & Johnson | 2 | $43 |
| Astellas Pharma US Inc | 3 | $41 |
| Lilly USA, LLC | 3 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Scilex Pharmaceuticals Inc. | 2 | $35 |
| Eisai Inc. | 2 | $33 |
| Exact Sciences | 2 | $32 |
| Medtronic | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Scynexis, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
How this compares
$2,502 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 523 | $641,151 |
| OzempicSemaglutide | 389 | $513,614 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 198 | $189,782 |
| EliquisApixaban | 214 | $173,473 |
| JardianceEmpagliflozin | 178 | $146,774 |
| FarxigaDapagliflozin Propanediol | 151 | $124,957 |
| TrulicityDulaglutide | 121 | $123,578 |
| JanuviaSitagliptin Phosphate | 95 | $82,894 |
| MyrbetriqMirabegron | 126 | $79,344 |
| LinzessLinaclotide | 101 | $73,322 |
| TradjentaLinagliptin | 76 | $69,533 |
| TrintellixVortioxetine Hydrobromide | 103 | $59,017 |
| Repatha SureclickEvolocumab | 76 | $51,244 |
| RybelsusSemaglutide | 39 | $41,853 |
| JanumetSitagliptin Phos/Metformin Hcl | 47 | $40,780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $41 | $764,729644 claims |
| Novo NordiskOzempic, Rybelsus | $354 | $555,467428 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $96 | $226,029271 claims |
| PfizerEliquis | $285 | $173,473214 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $147 | $143,712174 claims |
| AbbVieLinzess, Ubrelvy, Vraylar | $317 | $124,818140 claims |
| Astellas Pharma US IncMyrbetriq | $41 | $79,344126 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $37 | $59,017103 claims |
| NovartisEntresto | $156 | $15,39516 claims |
| BayerKerendia | $237 | $12,85720 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $19 | $11,33713 claims |
| Johnson & JohnsonXarelto | $43 | $11,32421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Sylacauga
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.